Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18254066 | 0.91 | HTT (0.81) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9340146 | 0.89 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL15346534 | 0.89 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9874334 | 0.89 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL29087602 | 0.87 | TGM2 (0.64) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL22300853 | 0.87 | HTT (0.67) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL6645232 | 0.87 | HTT (0.67) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL24990083 | 0.85 | TGM2 (0.65) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL19957878 | 0.85 | TGM2 (0.65) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL10828217 | 0.85 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165284-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165284-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | HTT 4515/4885LMNA 2872/4885SMN1; SMN2 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.